Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001037665 | SCV001201089 | likely benign | not provided | 2024-10-11 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV001195201 | SCV001365507 | likely benign | not specified | 2020-01-14 | criteria provided, single submitter | clinical testing | The p.Glu1682Lys variant in PCDH15 is classified as likely benign because it has been identified in 0.1% (35/24962) of African chromosomes by gnomAD (http://gnomad.broadinstitute.org), and computational prediction tools predict that this variant does not impact the protein. ACMG/AMP Criteria applied: BS1_Supporting, BP4. |
Ambry Genetics | RCV004958370 | SCV005465311 | uncertain significance | Inborn genetic diseases | 2024-12-03 | criteria provided, single submitter | clinical testing | The c.5044G>A (p.E1682K) alteration is located in exon 33 (coding exon 32) of the PCDH15 gene. This alteration results from a G to A substitution at nucleotide position 5044, causing the glutamic acid (E) at amino acid position 1682 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001272398 | SCV001454383 | uncertain significance | Usher syndrome type 1F | 2020-03-17 | no assertion criteria provided | clinical testing |